Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
681-700 of 1,743 trials

HIV Treatment Comparison: Doravirine vs. Dolutegravir

We are studying whether doravirine is as effective as dolutegravir for people newly diagnosed with HIV-1. The trial also examines potential side effects and health changes over time.

HIV Infection>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

HIV and HBV Co-Infection: Antiviral Treatment Strategies

We are studying two treatment reduction strategies for patients co-infected with HIV-1 and HBV to see how safely they can manage their viral infections. The trial will also look at the impact on quality of life and any potential side effects.

Co-infection with HIV-1 and HBV>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHepatologyInfectious Diseases

Crohn's Disease: Tulisokibart Treatment Study

We are testing a new medication, tulisokibart, for people with moderately to severely active Crohn's disease. The study aims to see if it helps reduce symptoms and achieve remission compared to a placebo.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Patellofemoral Osteoarthritis: Nasal Cartilage Implant Study

We are investigating whether a new treatment using engineered nasal cartilage can help reduce pain and improve knee function in people with osteoarthritis behind the kneecap. This study compares the new approach to standard treatments.

Knee OsteoarthritisPatellofemoral Osteoarthritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Advanced Solid Tumors: PM54 Treatment

We are testing a new treatment called PM54 for patients with advanced solid tumors. The goal is to evaluate its safety and how well it works compared to existing options.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

JJP-1212: New Immune Response Treatment

We are assessing whether JJP-1212 is safe and can effectively stimulate an immune response in humans. This study aims to understand its tolerability and potential benefits.

Linear IgA Bullous Dermatosis>2 yearsSafety phase (I)DermatologyInfectious Diseases

Primary IgA Nephropathy: Long-Term Study of Iptacopan

We are evaluating the long-term safety and tolerability of iptacopan in adults with primary IgA nephropathy. This study follows participants who have completed an earlier trial to see how well the treatment works over time.

IgA Nephropathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Acute Progressive Stroke: Norepinephrine Treatment

We are studying whether adding norepinephrine to standard care helps improve recovery in patients with acute progressive perforating artery stroke. The goal is to see if this combination leads to better functional outcomes and reduces complications.

Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Progressive Supranuclear Palsy: 18F-PI-2620 PET Imaging Study

We are investigating a new imaging tool to help identify and understand progressive supranuclear palsy in patients. This study may improve diagnosis and treatment options for this rare neurological condition.

Parkinson's DiseaseProgressive Supranuclear Palsy>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNeurology

Advanced Non-Small Cell Lung Cancer: New Immunotherapy Combinations

We are evaluating new combinations of immunotherapy for adults with untreated advanced non-small cell lung cancer. The goal is to see if these combinations are safe and more effective than standard treatment.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Mesothelioma: Pembrolizumab and Dendritic Cell Vaccine

We are studying a combination of pembrolizumab and a personalized vaccine for patients with advanced mesothelioma who have not responded to earlier treatments. The goal is to see if this approach can improve outcomes for these patients.

Mesothelioma>2 yearsSafety phase (I)Oncology

Sedation in Preterm Infants: Dexmedetomidine vs. Midazolam

We are comparing two sedation methods for very preterm infants on mechanical ventilation to see which one helps with extubation time and overall safety. This study will help us understand the best approach for sedation in these vulnerable patients.

Infant Sedation>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPediatrics

Triple-Negative Early Breast Cancer: Sacituzumab Govitecan with or without Pembrolizumab

We are comparing two treatment options for low-risk, triple-negative early breast cancer to see which is more effective. The study also evaluates how these treatments affect patients' quality of life.

Triple-Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Heart Failure: Stopping Beta-Blockers

We are studying whether discontinuing beta-blockers is as safe for patients with improved heart function as continuing the medication. This trial aims to understand the effects on heart failure relapse and overall heart health.

Heart Failure>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Advanced Malignancies: Testing DSB2455

We are assessing a new anti-cancer treatment, DSB2455, for patients with advanced malignancies. The goal is to understand how well it works when given alone.

Breast Cancer without Active Brain MetastasesProstate Cancer with Active Brain MetastasesOvarian Cancer without Active Brain Metastases>2 yearsSafety phase (I)Oncology

CDR404 for Solid Tumors

We are testing a new treatment called CDR404 in patients with specific solid tumors. The study aims to evaluate its safety and effectiveness in fighting cancer.

Solid Tumors>2 yearsSafety phase (I)Oncology

Familial Chylomicronemia Syndrome: AKCEA-APOCIII-LRX Study

We are testing a new subcutaneous treatment for patients with Familial Chylomicronemia Syndrome who have previously used volanesorsen. The study aims to evaluate its safety and how well it is tolerated.

Familial Chylomicronemia Syndrome>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyHematology

Diabetic Kidney Disease: Hyperpolarized MRI Study

We are investigating a new MRI technique to see if it can help classify the progression of diabetic kidney disease. This study aims to improve understanding of kidney function and metabolism in affected individuals.

Diabetic Kidney Disease>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyNephrology

Knee Osteoarthritis: Genicular Arteries Embolization Study

We are investigating whether a new procedure can help reduce knee pain in people with symptomatic knee osteoarthritis. Participants will compare this treatment to a sham procedure to assess its effectiveness.

Knee Osteoarthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Non-Small Cell Lung Cancer: Neoadjuvant and Adjuvant Treatment Study

We are studying a new treatment approach for patients with resectable non-small cell lung cancer to see if it improves tumor response and safety before and after surgery.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology